Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.69 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.69 |
| ▸ | BRAF | P15056 | 2/20 | 0.69 |
| ▸ | FLT4 | P35916 | 2/20 | 0.69 |
| ▸ | KDR | P35968 | 2/20 | 0.69 |
| ▸ | CIT | O14578 | 1/20 | 0.69 |
| ▸ | GAK | O14976 | 1/20 | 0.69 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.69 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.69 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.69 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.69 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.69 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.69 |
| ▸ | STK17B | O94768 | 1/20 | 0.69 |
| ▸ | STK10 | O94804 | 1/20 | 0.69 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.69 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.69 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.69 |
| ▸ | ABL1 | P00519 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3820465 | 1.00 | EGFR (0.69) | EGFRERBB2BRAFFLT4KDR | |
| SCHEMBL7622647 | 0.89 | EGFR (0.57) | EGFRERBB2BRAFFLT4KDR | |
| SCHEMBL28820784 | 0.87 | EGFR (0.70) | EGFRERBB2BRAFFLT4KDR | |
| SCHEMBL29882073 | 0.87 | EGFR (0.70) | EGFRERBB2BRAFFLT4KDR | |
| SCHEMBL3568126 | 0.85 | EGFR (0.69) | EGFRERBB2BRAFFLT4KDR | |
| SCHEMBL3520111 | 0.82 | EGFR (0.72) | EGFRERBB2KDRCITGAK | |
| Gefitinib SCHEMBL29351336 | 0.82 | EGFR (1.00) | EGFRERBB2BRAFFLT4KDR | |
| SCHEMBL12308286 | 0.82 | EGFR (0.77) | EGFRERBB2BRAFFLT4KDR | |
| Gefitinib SCHEMBL29351046 | 0.82 | EGFR (1.00) | EGFRERBB2BRAFFLT4KDR | |
| Gefitinib SCHEMBL465143 | 0.82 | EGFR (1.00) | EGFRERBB2BRAFFLT4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119768401-A | Bicyclic tetrahydrothiazepine derivatives | 豪夫迈·罗氏有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-113999249-B | Methods for preparing tricyclic PI3K inhibitor compounds and methods of treating cancer using the same | 基因泰克公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-119661711-A | CD8 binding agents and uses thereof | 豪夫迈·罗氏有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-119677843-A | Novel inhibitors of histone methyltransferase nuclear localization | 昆士兰医学研究所理事会 | 2025-03-21 | — | — | CN | disclosed |
| CN-119677733-A | Bicyclic tetrahydrothiazepine derivatives | 豪夫迈·罗氏有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-119604530-A | Administration of treatment with anti-FCRH 5/anti-CD 3 bispecific antibodies | 基因泰克公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-119585308-A | Administration of therapy with anti-FCRH 5/anti-CD 3 bispecific antibodies | 基因泰克公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119546334-A | Methods for treating previously untreated follicular lymphoma with Mo Suni tobulab and lenalidomide | 基因泰克公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119487067-A | Administration of treatment with anti-FCRH 5/anti-CD 3 bispecific antibodies | 基因泰克公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119365466-A | Tricyclic pyridones and pyrimidinones | 医睿世康药业研发公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-117098537-A | Combination therapy for cancer treatment | 医睿世康药业研发公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-114867494-B | anti-LY 6G6D antibodies and methods of use | 基因泰克公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-116568824-A | Method for diagnosing and treating lymphoma | 基因泰克公司 | 2023-08-08 | — | — | CN | disclosed |
| CN-116234797-A | Heterocyclic inhibitors of TEAD for the treatment of cancer | 基因泰克公司 | 2023-06-06 | — | — | CN | disclosed |
| CN-107207493-B | Substituted pyrrolopyridines as bromodomain inhibitors | 基因泰克公司 | 2023-01-20 | — | — | CN | disclosed |
| CN-115583947-A | Substituted pyrrolopyridines as bromodomain inhibitors | 基因泰克公司 | 2023-01-10 | — | — | CN | disclosed |
| CN-114555116-A | Administration for anti-TIGIT and anti-PD-L1 antagonist antibody therapy | 豪夫迈·罗氏有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-107406414-B | (piperidin-3-yl) (naphthalen-2-yl) methanone derivatives as inhibitors of histone demethylase KDM2B for the treatment of cancer | 基因泰克公司 | 2022-04-19 | — | — | CN | disclosed |
| CN-114269376-A | Methods of treating cancer with anti-PD-L1 antibodies | 豪夫迈·罗氏有限公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-108026110-B | Fused tricyclic compounds as protein kinase inhibitors | 国家公共部门基金会卡洛斯三世国家癌症研究中心(F.S.P.CNIO) | 2022-02-08 | — | — | CN | disclosed |